The stock of Aequus Pharmaceuticals Inc (CVE:AQS) hit a new 52-week low and has $0.26 target or 10.00% below today’s $0.29 share price. The 9 months bearish chart indicates high risk for the $12.56M company. The 1-year low was reported on Sep, 13 by Barchart.com. If the $0.26 price target is reached, the company will be worth $1.26 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 67,500 shares traded hands or 184.93% up from the average. Aequus Pharmaceuticals Inc (CVE:AQS) has risen 6.00% since August 14, 2016 and is uptrending. It has underperformed by 10.49% the S&P500.
Aequus Pharmaceuticals Inc. is a specialty pharmaceutical firm focused on developing and commercializing products. The company has a market cap of $12.56 million. The Firm operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. It currently has negative earnings. The Company’s products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release , which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.